Heart transplant study tests safer CMV prevention

NCT ID NCT07079735

First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 31 times

Summary

This study compares two drugs, letermovir and valganciclovir, to see which is safer and more effective at preventing CMV infection in heart transplant patients at moderate to high risk. About 150 adults who have recently received a heart transplant will take one of the two medications. The goal is to reduce side effects like low white blood cell counts while keeping patients free from CMV.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CMV VIREMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Columbia University/NYP Milstein Hospital

    RECRUITING

    New York, New York, 10032, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • NYP-Weill Cornell

    RECRUITING

    New York, New York, 10021, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.